07:40 AM EST, 03/08/2024 (MT Newswires) -- Numinus Wellness Inc. ( NUMIF ) , a mental health care company advancing behavioral health treatments, on Friday noted "positive" data generated from Mind Medicine in its Phase 2b clinical trial of MM120 (lysergide d-tartrate) for the treatment of generalized anxiety disorder. The study removed variables such as additional medications and psychotherapy so the effects of MM120 were isolated and fully evaluated.

The study showed that four weeks after a single 100-microgram dose of MM120, 48% of the participants achieved remission and no longer showed clinically significant anxiety, and 65% showed clinically meaningful improvement. Based on initial clinical data from the Phase 2b trial and the significant unmet medical need in treating GAD, the FDA has designated MM120 for GAD as a breakthrough therapy.

The research was conducted over 20 clinical trial sites with 198 participants. Numinus' Cedar Clinical Research Draper Utah research clinic was among the highest enrolling sites for the study, with its clinic at Murray, Utah, also participating. Dr. Reid Robison, Numinus' Chief Clinical Officer and Dr. Paul Thielking, Chief Science Officer, were Principal Investigators.

"We were pleased to participate in this trial of MM120, with the results indicating a robust and durable improvement for trial participants with GAD. This is an important development in treating a condition that is considered the second most common mental health condition among American adults," said Dr. Robison.